정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2081 | Recruiting | Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 | Severe Acute Respiratory Syndrome | Drug: Camostat Mesilate Other: Standard of Care |
Phase 2 | Alan Bryce | OTHER | 264 | All | 18 Years | Mayo Clinic in Arizona, Scottsdale, Arizona, United States Tucson Medical Center, Tucson, Arizona, United States Mayo Clinic in Florida, Jacksonville, Florida, United States |
2080 | Completed | Camostat Mesylate in COVID-19 Outpatients | COVID-19 | Drug: Camostat Mesilate Other: Placebo |
Phase 2 | Yale University | OTHER | 74 | All | 18 Years | Yale University, New Haven, Connecticut, United States |
2079 | Terminated | Camostat With Bicalutamide for COVID-19 | Coronavirus Infection | Drug: Camostat Mesilate Drug: Bicalutamide 150 mg |
Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | OTHER | 6 | All | 60 Years | Johns Hopkins Hospital, Baltimore, Maryland, United States |
2078 | Recruiting | CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients | Covid19 | Drug: Camostat Mesylate Drug: Placebo |
Phase 3 | Assistance Publique - Hopitaux de Paris | OTHER | 596 | All | 18 Years | Centre Hospitalier Victor Dupouy, Argenteuil, France AP-HP Hopital Henri Mondor, Creteil, France Centre Hospitalier Sud Ile de France - Melun, Melun, France AP-HP Hopital Bichat, Paris, France APHP - Saint Louis, Paris, France Centre de Sante Richerand, Paris, France |
2077 | Completed | Canakinumab in Covid-19 Cardiac Injury (The Three C Study) | SARS-CoV 2 | Drug: Canakinumab Injection 600mg Drug: Canakinumab Injection 300mg Drug: Placebos |
Phase 2 | The Cleveland Clinic, Novartis | OTHER | 45 | All | 18 Years | Cleveland Clinic Florida, Weston, Florida, United States Cleveland Clinic, Cleveland, Ohio, United States |
2076 | Completed | Canakinumab in Patients With COVID-19 and Type 2 Diabetes | Diabetes Mellitus, Type 2 | Drug: Canakinumab Drug: Placebo |
Phase 3 | University Hospital, Basel, Switzerland, Novartis, Swiss National Science Foundation | OTHER | 116 | All | 18 Years | University Medical Clinic Aarau, Aarau, Switzerland University Hospital Basel, Basel, Switzerland University Hospital Bern, Bern, Switzerland Hopital du Jura, Delemont, Switzerland University Hospital Geneva, Geneva, Switzerland University Hospital Lausanne, Lausanne, Switzerland Cantonal Hospital Lucerne, Luzern, Switzerland Cantonal Hospital St Gallen, St. Gallen, Switzerland University Hospital Zurich, Zurich, Switzerland |
2075 | Completed | Cannabidiol Bioavailability Trial With Oral Multiple Dose Administration | Comparative Bioavailability | Drug: GLA-015 Drug: DAC C-052 "Cannabidiol" / NRF 22.10 "Oily cannabidiol solution 100 mg/ml" |
Phase 1 | SocraTec R&D GmbH, Glatt Pharmaceutical Services GmbH & Co. KG, SocraMetrics GmbH | OTHER | 18 | All | 18 Years | SocraTec R&D GmbH Clinical Pharmacology Unit, Erfurt, Thuringia, Germany |